Multicenter Retrospective Study of the Impact of Localized Therapy on Prognosis in Patients With Oligometastatic Solid Tumors.
6 affiliations
- 1Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- 2Department of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- 3Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- 4Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- 5Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- 6Center of Precision Medicine, Shenshan Central Hospital, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, China.
Abstract
Local therapy has recently been applied to treat oligometastatic cancer across various malignant cancers. However, definitive evidence for local treatment regimens remains lacking. We aimed to evaluate the clinical outcomes of combining local therapy with systemic treatment for patients with oligometastatic solid tumors including breast cancer, liver cancer, and non-small cell lung cancer (NSCLC) in a multicenter retrospective study. From January 2013 to December 2023, 575 patients with fewer than or equal to five metastases of breast cancer, liver cancer, and NSCLC in three tertiary university hospitals were analyzed retrospectively. The primary endpoint was overall survival (OS). The secondary endpoints included progression-free survival (PFS) and prognostic factors affecting the treatment outcomes. Before propensity score matching, significant differences were observed in both OS and PFS between the local therapy plus systemic therapy and systemic therapy alone groups (p < 0.001 and p < 0.001). After PSM, PFS remained significantly different (p = 0.017), but OS did not (p = 0.076). In liver cancer, before PSM analysis showed a significant PFS benefit (p = 0.011), which was absent after PSM for both OS and PFS (p = 0.568 and p = 0.363). For both breast cancer and NSCLC patients, no significant differences in OS or PFS were found after PSM. Local treatment of solitary metastatic lesions showed that no statistically significant difference was observed in OS or PFS of patients with advanced oligometastatic breast, liver cancer, and NSCLC.
Related
- An Early Longitudinal Decrease in Platelet Count Is Associated With Poor Prognosis in Acute Myocardial Infarction Patients: A Multicenter Retrospective Study.
- Impact of different follow-up methods on prognosis of diabetic foot patients after endovascular treatment: a multicenter retrospective cohort study.
- 971 The impact of liver metastases on immune-related adverse events in stage IV patients treated with immune-checkpoint inhibitors: a real-world, multicenter, retrospective study
- Analysis of factors influencing short-term prognosis in patients with chronic subdural hematoma: A single-center retrospective cohort study
- Clinical characteristics and prognosis of liver injury in patients receiving immune checkpoint inhibitor-based therapy: a real-world retrospective study
BibTeX
@article{deng2026multicenter,
title = {{Multicenter Retrospective Study of the Impact of Localized Therapy on Prognosis in Patients With Oligometastatic Solid Tumors.}},
author = {Xueman Deng and Duoguang Wu and Luting Ni and Wei Li and Zhijun Liu and Jiewei Liu and Jieqiong Liu},
journal = {Cancer medicine},
year = {2026},
month = nov,
doi = {10.1002/cam4.72280},
url = {https://europepmc.org/article/MED/42998017},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Multicenter Retrospective Study of the Impact of Localized Therapy on Prognosis in Patients With Oligometastatic Solid Tumors.
AU - Xueman Deng
AU - Duoguang Wu
AU - Luting Ni
AU - Wei Li
AU - Zhijun Liu
AU - Jiewei Liu
AU - Jieqiong Liu
PY - 2026
DA - 2026/11/01
JO - Cancer medicine
DO - 10.1002/cam4.72280
UR - https://europepmc.org/article/MED/42998017
AB - Local therapy has recently been applied to treat oligometastatic cancer across various malignant cancers. However, definitive evidence for local treatment regimens remains lacking. We aimed to evaluate the clinical outcomes of combining local therapy with systemic treatment for patients with oligometastatic solid tumors including breast cancer, liver cancer, and non-small cell lung cancer (NSCLC) in a multicenter retrospective study. From January 2013 to December 2023, 575 patients with fewer than or equal to five metastases of breast cancer, liver cancer, and NSCLC in three tertiary university hospitals were analyzed retrospectively. The primary endpoint was overall survival (OS). The secondary endpoints included progression-free survival (PFS) and prognostic factors affecting the treatment outcomes. Before propensity score matching, significant differences were observed in both OS and PFS between the local therapy plus systemic therapy and systemic therapy alone groups (p < 0.001 and p < 0.001). After PSM, PFS remained significantly different (p = 0.017), but OS did not (p = 0.076). In liver cancer, before PSM analysis showed a significant PFS benefit (p = 0.011), which was absent after PSM for both OS and PFS (p = 0.568 and p = 0.363). For both breast cancer and NSCLC patients, no significant differences in OS or PFS were found after PSM. Local treatment of solitary metastatic lesions showed that no statistically significant difference was observed in OS or PFS of patients with advanced oligometastatic breast, liver cancer, and NSCLC.
SN - 2045-7634
ER -